News
From Lab to Launch: Understanding Life Sciences, Healthcare & Pharma Meetings
In the world of professional meetings and events, few sectors are as complex, as regulated, or as consequential as life sciences. Yet the terms life sciences, healthcare, and pharmaceutical are used interchangeably and often incorrectly. Understanding the distinctions between them is the foundation for understanding why the meetings that serve these industries look so different from every other corporate sector. That’s why we’ve created this definitive guide to the industry landscape, the distinctions that matter, and the meetings that drive every stage of the drug and device development lifecycle.
DEFINITIONS
The umbrella term encompassing all scientific disciplines focused on living organisms. This includes pharmaceuticals, biotechnology, medical devices, diagnostics, genomics, agricultural sciences, and environmental sciences. Any company researching, developing, or commercialising products derived from biology or chemistry operates in life sciences.
The organised system for maintaining or improving human health. Healthcare is where life sciences outputs – drugs, devices, diagnostics – are applied by professionals to patients. It encompasses hospitals, clinics, payers, health systems, patient advocacy groups, and the healthcare professionals (HCPs) who deliver care.
The branch of life sciences focused specifically on developing, manufacturing, and marketing medicines for human or veterinary use. Pharmaceutical companies (“pharma”) include large multinationals, specialty players, and emerging biotechs. They are the primary clients of life sciences meetings management agencies
Why the distinction matters for meetings: A pharmaceutical company conducts investigator meetings and advisory boards to develop a drug. A healthcare organisation hosts HCP education events and clinical training. A life sciences company may do both, plus launch events, congresses, and incentive programs. The regulatory requirements, compliance obligations, and stakeholder audiences differ significantly and so must the approach of any meetings agency serving them.
PHASE 1: DISCOVERY & PRE-CLINICAL RESEARCH
Before a molecule becomes a medicine, years of laboratory and pre-clinical research take place. This phase is largely internal with scientists, researchers, and R&D leads working within the company and in collaboration with academic institutions, contract research organisations (CROs), and key opinion leaders (KOLs) in the relevant therapeutic area.
Meetings at this stage are typically smaller, scientifically intensive, and focused on alignment, data sharing, and strategic direction. The outputs are decision gates: does this compound warrant further investment? What does the scientific literature say? Who are the leading academic voices we need to engage?
Even at this early stage, compliance is relevant. Any engagement with external academics or HCPs, even informally, may fall under EFPIA (European Federation of Pharmaceutical Industries and Associations) or PhRMA codes and must be documented accordingly.
Key meeting & event types at this phase
Cross-functional R&D gatherings to align on pipeline priorities, share preclinical data, and determine which compounds advance. Typically confidential, requiring secure event environments and NDA-compliant logistics.
Small, select meetings bringing together leading external scientists, academics, and HCPs to advise on the scientific rationale, unmet need, and early development strategy for a compound. Often 6–12 attendees.
Facilitated sessions between company scientists and university research teams. May include virtual formats for global academic collaboration across multiple geographies simultaneously.
Webinar-style engagements used to brief external experts on emerging data or to receive their input. Virtual formats are well-suited here for their accessibility and lower cost at the pre-investment stage.
PHASE 2: CLINICAL TRIALS & DEVELOPMENT
Clinical development is the most meeting-intensive phase in the drug lifecycle. As a compound moves through Phase I (first-in-human safety studies), Phase II (efficacy and dosing), and Phase III (large-scale efficacy and safety across populations), the number of stakeholders involved grows dramatically. Trial sites may span dozens of countries; hundreds of investigators and clinical research associates (CRAs) must be aligned, trained, and kept engaged.
This is where specialist life sciences meetings management becomes indispensable. Investigator meetings, arguably the most distinctive event type in the pharma sector, are operationally complex, globally distributed, and carry significant regulatory weight. The people attending them are busy clinicians who need precise logistics, compliant hospitality, and high-quality scientific content.
Simultaneously, companies engage their advisory boards more frequently at this phase to sense-check trial design, interpret emerging data, and begin shaping the clinical narrative that will eventually support regulatory submissions.
Key meeting & event types at this phase
The backbone of clinical development events. Investigator meetings bring together the physicians, nurses, and coordinators running trial sites to receive protocol training, safety updates, and enrolment support. They typically happen at trial kick-off and at each new phase transition. Global scope means complex multi-country logistics, translation needs, and simultaneous interpretation requirements.
Smaller, governance-focused sessions bringing together the trial’s senior investigators and company sponsors to review cumulative data, make protocol amendment decisions, and oversee trial integrity. Typically quarterly, often hybrid to accommodate global participants.
External expert panels, usually KOLs and clinical investigators, convened to advise on trial outcomes, endpoint selection, and statistical interpretation. These boards may meet multiple times per year as data matures, with strict documentation of all HCP engagements for compliance reporting.
Internal and CRO-facing training sessions for the monitors who oversee trial sites. These are logistics-heavy events that may require certification-level tracking of attendance and competency assessment.
Virtual or in-person touchpoints delivered to individual trial sites to maintain engagement, update on protocol amendments, and ensure continued patient enrolment. The growing adoption of virtual formats has made these more cost-efficient and accessible for busy site staff.
Independent expert reviews of accumulating trial safety data. These meetings are highly confidential and require secure environments and are increasingly delivered as virtual sessions with strict access controls.
Compliance note: Every interaction with an external investigator or HCP at these meetings generates a “transfer of value” – hospitality, travel, honoraria – that must be reported under the EFPIA Disclosure Code in Europe, the Sunshine Act (Open Payments) in the US, and equivalent national regulations elsewhere. A specialist meetings agency must have these reporting workflows built into their event operations from day one, not retrofitted afterwards.
PHASE 3: REGULATORY & MEDICAL AFFAIRS
As a drug approaches regulatory submission – whether to the FDA, EMA, or national health authorities – a new category of meetings begins to emerge. The science is maturing; the company now needs to build a scientific narrative around its data, engage the clinical and payer communities, and prepare for the commercial moment ahead.
This is the domain of Medical Affairs, the function that sits between clinical development and commercial, acting as the scientific steward of the asset. Medical Affairs meetings are non-promotional; their purpose is education, scientific exchange, and gathering insights from the clinical community to inform label strategy and real-world evidence planning.
Simultaneously, companies begin appearing prominently at medical congresses – the major annual gatherings of therapeutic area specialists – where data can be presented, visibility established, and relationships with KOLs deepened before commercial activities begin.
Key meeting & event types at this phase
Large-scale, multi-day scientific gatherings organised by medical associations such as ESC (cardiology), ASCO (oncology), or EASD (diabetes). Pharmaceutical companies attend as sponsors, presenting data through poster sessions, oral presentations, and sponsored symposia. Congress participation requires significant logistics: booth building, delegate management, hotel blocks, hospitality suites, and satellite symposia planning.
Company-sponsored scientific sessions held in conjunction with a major congress, typically the evening before or during breaks. A satellite symposium is one of the highest-value meeting formats in pharma: a captive audience of specialists, a faculty of leading KOLs, and a tightly structured scientific programme. They require meticulous speaker management, AV production, and catering compliance with local regulations.
Non-promotional advisory meetings convened by Medical Affairs to gather clinical insights on unmet need, treatment patterns, and the scientific questions practitioners most want answered. These boards inform label discussions, post-marketing study designs, and clinical guidelines strategies.
Structured, ongoing engagement with key opinion leaders who will shape clinical adoption. Includes one-to-one meetings, small roundtables, and international faculty programmes. All subject to strict fair market value (FMV) payment guidelines and transfer-of-value reporting.
The virtual format has become standard for advisory boards where attendees are geographically dispersed or schedules are too constrained for in-person. Virtual and hybrid advisory boards demand sophisticated platform management to maintain the quality of scientific discourse and engagement.
Internal alignment meetings bringing together Medical Affairs, Regulatory, Market Access, and Commercial teams to agree on scientific messaging, publication strategy, and HCP education priorities ahead of approval.
PHASE 4: COMMERCIAL LAUNCH & SALES ACTIVATION
Regulatory approval triggers one of the most energetic periods in a pharmaceutical company’s calendar. The commercial launch is not a single event but a cascade of them – internal celebrations and briefings, field force training, HCP education programmes, and promotional meetings that must all align with an approved label and comply with promotional codes.
This phase introduces a fundamentally different regulatory environment. Commercial meetings are promotional and subject to the ABPI Code (in the UK), EFPIA in Europe, PhRMA in the US, and equivalent national codes. This means every claim made about the product, every piece of material used, and every HCP interaction must be approved by medical, legal, and regulatory teams.
The scale of meetings also increases dramatically. National sales meetings can involve hundreds or thousands of field-based employees. Speaker bureau programs deploy trained HCPs to educate their peers at local and regional level. The meetings management challenge shifts from scientific precision to operational scale.
Key meeting & event types at this phase
The commercial launch event is often one of the largest single meetings a pharma company holds. It may be split into internal (field force briefing, galvanising the sales organisation around the new product) and external (HCP education and awareness) components, with significant production value, creative direction, and brand experience design.
Annual or bi-annual gatherings of the entire commercial field force, sometimes thousands of attendees. NSMs combine scientific updates, sales training, motivational programming, and brand campaigns. They require the full spectrum of meetings management: air travel, hotel blocks, general session production, breakout logistics, and evening entertainment, all with complex compliance requirements around any HCP attendance.
Before an HCP can speak on behalf of a pharmaceutical company at a promotional event, they must be formally trained and accredited. Speaker training meetings are intensive, compliance-heavy events combining scientific education, presentation skills coaching, and sign-off on approved materials. The training and credentialing records must be maintained and auditable.
Promotional education meetings where trained HCP speakers present to their clinical peers – typically in local restaurant settings, hotel meeting rooms, or virtually. These are among the most compliance-sensitive events in pharma: every attendee must be a genuine HCP with a legitimate educational need, hospitality must fall within local code limits, and all transfers of value must be reported.
Standalone, company-organised sessions held within a congress exhibition hall or adjacent meeting space separate from the scientific programme. Product theatres allow promotional messaging to be delivered in a congress environment and require careful separation from any non-promotional medical affairs activities at the same event.
Smaller-format commercial meetings for regional field force teams – quarterly business reviews, territory strategy sessions, and new-hire onboarding meetings. These are high in volume, moderate in size, and benefit from a managed meetings programme to achieve cost efficiency and compliance consistency.
Key compliance distinction: Once a product is commercially available, meetings involving HCPs bifurcate into promotional (subject to advertising codes, requiring MLR approval of all materials) and non-promotional medical affairs (governed by scientific exchange principles). A specialist meetings agency must understand this boundary and ensure that operational processes, from invitation wording to hospitality budgets, respect it at every point.
PHASE 5: POST-LAUNCH LIFECYCLE MANAGEMENT, INCENTIVES & ENGAGEMENT
After launch, the meetings cadence does not slow, it deepens and diversifies. Companies must sustain commercial momentum, generate real-world evidence to broaden the label or defend reimbursement, manage new indications or formulations, and, critically, retain and motivate the commercial teams delivering results in the field.
This is the phase at which incentive programs become a major meetings category. President’s Clubs, sales performance reward travel, and recognition events are powerful retention and motivation tools. In life sciences, they carry their own compliance considerations: field force incentive trips must be clearly separated from any HCP engagement activities.
Post-launch also sees increasing investment in patient-centric events – meetings involving patient advocacy groups, patient advisory boards, and disease awareness initiatives – reflecting the industry’s growing commitment to placing patients at the centre of its strategy.
Key meeting & event types at this phase
Performance-based reward programmes for top-achieving field force, often involving international travel to aspirational destinations. These are high-value, high-visibility events that require creative design, exceptional experience management, and clear separation from any promotional or medical activities. They are a powerful tool for talent retention and cultural cohesion.
Internal events celebrating commercial, scientific, and cultural achievements. Awards dinners, regional celebrations, and leadership recognition events. Proske’s work on President’s Club programmes for pharma clients exemplifies the blend of experiential design and compliance-aware logistics these events demand.
As products mature, Medical Affairs convenes advisory boards to design and interpret real-world studies – observational research conducted in actual clinical practice to complement trial data. These non-promotional boards continue to require full HCP engagement compliance and transfer-of-value reporting.
Accredited education programmes for HCPs, typically independently organised but sometimes industry-supported. CME events must demonstrate genuine scientific independence, with company involvement strictly governed by accreditation body and industry code requirements.
Meetings convening patient advocacy representatives to provide insights on disease experience, treatment burden, and unmet needs. These are growing in importance as regulatory bodies and payers increasingly expect evidence of patient engagement in development and commercial strategy.
Internal strategic events where brand, medical, market access, and commercial teams align on the annual plan to review performance data, competitive landscape, and adjusting tactics. Often combined with leadership summits and cross-functional workshops.
VIRTUAL & HYBRID:
A FORMAT, NOT A PHASE NOTE
Virtual and hybrid meetings are not a separate category in the life sciences meetings landscape, they are a delivery format that can be applied to almost any of the meeting types described above. Understanding when to use each format is a matter of strategic judgment, not default preference.
In-person remains the gold standard for high-stakes scientific exchange, investigator engagement, and commercial launch moments. The quality of relationship-building, the credibility of scientific discourse, and the energy of a product launch cannot be fully replicated digitally.
Virtual formats excel for geographically dispersed audiences, high-frequency touchpoints (site refresh meetings, monthly advisory board check-ins), and cost-sensitive early-phase events. They also democratise access – a virtual satellite symposium can reach HCPs who could never travel to a congress.
Hybrid events offer both reach and depth, but they are the most demanding to produce well. A hybrid investigator meeting serving 200 in-room and 400 virtual participants requires two fully designed experiences, not one with a camera in the corner. The production complexity and compliance tracking (for both virtual and in-person HCP attendees) must be planned from the outset.
At Proske, we plan the format decision strategically: who needs to be in the room, who can be served virtually, what engagement outcomes are required, and how compliance documentation must flow across both channels.
How Proske Serves LIFE SCIENCES MEETINGS & EVENTS
With four decades of healthcare and pharma meetings expertise, Proske brings compliance fluency, scientific understanding, and operational excellence to every phase of the drug and medical device development journey.
Compliance-First Delivery
Built-in EFPIA, PhRMA, ABPI, and GDPR compliance. Integrated with Veeva, Concur, and Cvent for HCP spend tracking and transfer-of-value reporting from day one.
Strategic Meetings Management
SMM programs that deliver visibility, savings, and control across your entire meetings portfolio – from small advisory boards to national field force events.
Scientific & Creative Excellence
We understand the science as well as the staging. Our teams deliver high-quality and engaging programs – satellite symposia, congress presence and hybrid investigator meetings, working together with our clients and their MedCom agencies.
Global Delivery Network
Trusted partners in every major market, enabling consistent local execution across the global trial and commercial footprint of international pharmaceutical organizations.
Technology & AI Integration
AI-powered efficiencies in attendee management, real-time reporting dashboards, and digital event platforms that deliver insight and control across your meetings program.
Incentive & Experience Design
From President’s Club programmes to awards evenings, our experiential design team creates moments that motivate, reward, and build the cultures that drive commercial performance.
